

Veloxa Chewable Tablets for Dogs

Authorised

- Febantel
- Pyrantel
- Praziquantel

Product identification

Medicine name:

Veloxa Chewable Tablets for Dogs

Veloxa 150/144/50 mg tyggetabletter til hund

Active substance:

Febantel

Pyrantel

Praziquantel

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Febantel

150.00 milligram(s) / 1.00 Tablet

Pyrantel

50.00 milligram(s) / 1.00 Tablet

Praziquantel

50.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP52AA51

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Norway

Package description:

PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 52 blister strips of 2 chewable tablets (104 chewable tablets)

PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 13 blister strips of 8 chewable tablets (104 chewable tablets)

PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 1 blister strip of 2 chewable tablets (2 chewable tablets)

PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 2 blister strips of 2 chewable tablets (4 chewable tablets)

PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 1 blister strips of 8 chewable tablets (8 chewable tablets)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Lavet Kft.

Marketing authorisation date:

11/09/2012

Manufacturing sites for batch release:

Lavet Kft.

Responsible authority:

Norwegian Medical Products Agency

Authorisation number:

12-9036

Date of authorisation status change:

4/04/2017

Reference member state:

Hungary

Procedure number:

HU/V/0116/001

Concerned member states:

Austria Belgium Finland France Germany Greece Ireland Italy Luxembourg
Netherlands Norway Portugal Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.